Moreover, because the PI3 K/Akt pathway, which is downstream of HER3, plays an important role in cancer progression and drug resistance, it is reasonable to hypothesize that PI3 K/Akt inhibitors can also enhance the antitumor activity of HER-targeted drugs. Here, ERBB3 is linked to cancer.